Due to management changes the overall state of the company seems to be in turmoil, and it is making questionable decisions around drug studies according the author.
Read the Full Story at seekingalpha.com
What Is Going On At Axovant Sciences?
More from BusinessMore posts in Business »
- Biogen Stays the Wrong Course After a Key Drug Failure
- What Happened? Alzheon Leaves IPO on the Table for the Second Time | Biospace
- Biogen Inks Two Deals to Make Drugs for Neurological Diseases | NASDAQ
- AC Immune inks $1.7bn deal with Lilly, strategic partnership with WuXi | Outsourcing Pharma
- BioXcel Announces Positive Data On Senile Dementia Of Alzheimer’s Type; Stock Up | NASDAQ